- Home
- NAN vs CELC Comparison
NAN vs CELC Comparison
Compare NAN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAN
- CELC
- Stock Information
- Founded
- NAN 1999
- CELC 2011
- Country
- NAN United States
- CELC United States
- Employees
- NAN N/A
- CELC N/A
- Industry
- NAN Investment Managers
- CELC Medical Specialities
- Sector
- NAN Finance
- CELC Health Care
- Exchange
- NAN Nasdaq
- CELC Nasdaq
- Market Cap
- NAN 352.5M
- CELC 327.3M
- IPO Year
- NAN N/A
- CELC 2017
- Fundamental
- Price
- NAN $11.15
- CELC $10.24
- Analyst Decision
- NAN
- CELC Strong Buy
- Analyst Count
- NAN 0
- CELC 6
- Target Price
- NAN N/A
- CELC $30.17
- AVG Volume (30 Days)
- NAN 74.6K
- CELC 392.7K
- Earning Date
- NAN 01-01-0001
- CELC 05-14-2025
- Dividend Yield
- NAN 4.37%
- CELC N/A
- EPS Growth
- NAN N/A
- CELC N/A
- EPS
- NAN N/A
- CELC N/A
- Revenue
- NAN N/A
- CELC N/A
- Revenue This Year
- NAN N/A
- CELC N/A
- Revenue Next Year
- NAN N/A
- CELC N/A
- P/E Ratio
- NAN N/A
- CELC N/A
- Revenue Growth
- NAN N/A
- CELC N/A
- 52 Week Low
- NAN $9.11
- CELC $7.58
- 52 Week High
- NAN $11.34
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- NAN 40.73
- CELC 54.38
- Support Level
- NAN $11.11
- CELC $7.58
- Resistance Level
- NAN $11.26
- CELC $10.48
- Average True Range (ATR)
- NAN 0.21
- CELC 1.04
- MACD
- NAN -0.01
- CELC 0.17
- Stochastic Oscillator
- NAN 49.46
- CELC 80.01
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.